{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:36:47Z","timestamp":1774611407074,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.revmed.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T09:31:07Z","timestamp":1382088667000},"page":"466-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prise en charge th\u00e9rapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies n\u00e9crosantes auto-immunes"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Tournadre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2013.09.008_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis [first of two parts]","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2013.09.008_bib0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trila design in adult idiopathic inflammatory myopathies, with the exception of inclusion-body myositis","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.revmed.2013.09.008_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies. Analysis of 100\u00a0french canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2013.09.008_bib0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.revmed.2012.07.018","article-title":"Acquired necrotizing myopathies","volume":"34","author":"Allenbach","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.09.008_bib0025","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nrrheum.2013.26","article-title":"A critical role for immature muscle precursors in myositis","volume":"9","author":"Tournadre","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0030","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"15","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.revmed.2013.09.008_bib0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized pilot trial of etanercept in dermatomyositis","volume":"70","author":"The Muscle Study Group","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0040","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"Van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.revmed.2013.09.008_bib0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2013.09.008_bib0055","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.revmed.2013.09.008_bib0060","first-page":"2058","article-title":"Randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis","volume":"58","author":"Coyle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2013.09.008_bib0070","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","article-title":"Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality","volume":"41","author":"Sultan","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2013.09.008_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000338474","article-title":"Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy","volume":"68","author":"Uchino","year":"2012","journal-title":"Eur Neurol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0090","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.1780300312","article-title":"Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis","volume":"30","author":"Laxer","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0095","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/art.23829","article-title":"The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis","volume":"59","author":"Seshadri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0100","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1668::AID-MUS7>3.0.CO;2-#","article-title":"Frequency of relapses in patients with polymyositis and dermatomyositis","volume":"21","author":"Phillips","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2013.09.008_bib0105","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: long-term follow-up","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.revmed.2013.09.008_bib0115","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/art.21378","article-title":"The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids","volume":"52","author":"Ramanan","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2013.09.008_bib0120","first-page":"S53","article-title":"Randomised double-blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy","volume":"199","author":"Miller","year":"2002","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.revmed.2013.09.008_bib0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsky","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0130","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4\u00a0cases","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.09.008_bib0140","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10067-006-0526-5","article-title":"Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature","volume":"26","author":"Caramaschi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0155","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0160","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","article-title":"Mycophenolate mofetil treatment in resistant myositis","volume":"46","author":"Pisoni","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0165","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","article-title":"Mycophenolate mofetil in dermatomyositis: is it safe?","volume":"66","author":"Rowin","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2013.09.008_bib0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e31818d094b","article-title":"Experience of mycophenolate mofetil in 10\u00a0patients with autoimmune-related interstitial lung disease demonstrates promising effects","volume":"337","author":"Saketkoo","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.revmed.2013.09.008_bib0175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mus.10026","article-title":"Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome","volume":"25","author":"Schneider","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2013.09.008_bib0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2007.08.014","article-title":"Leflunomide as adjuvant treatment of dermatomyositis","volume":"58","author":"Boswell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/08916930600623874","article-title":"Anti-Jo-1\u00a0antibody positive polymyositis \u2013 successful therapy with leflunomide","volume":"39","author":"Lange","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.revmed.2013.09.008_bib0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.2007.073221","article-title":"Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis","volume":"67","author":"Sangle","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","article-title":"Th1\u00a0and Th17\u00a0balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins","volume":"46","author":"Tournadre","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.revmed.2013.09.008_bib0205","first-page":"397","article-title":"The effect of intravenous immunoglobulin [IVIG] treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0210","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulins treatment in polymyositis\/dermatomyositis","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0220","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73\u00a0patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0225","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strenght in anti-3-hydroxy-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0230","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0235","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.11-0492","article-title":"IV immunoglobulin might be considered as a first-line treatment of severe interstitial lung disease associated with polymyositis","volume":"140","author":"Diot","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2013.09.008_bib0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polmyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2013.09.008_bib0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2013.09.008_bib0250","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2004.032359","article-title":"Contribution of tumour necrosis factor alpha and interleukin [IL] 1beta to IL6\u00a0production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors","volume":"64","author":"Chevrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0260","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0265","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: a case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0270","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0275","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1\u00a0or anti-Ro 52\/anti-Ro 60\u00a0autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 10","key":"10.1016\/j.revmed.2013.09.008_bib0280","first-page":"589","article-title":"Anakinra with refractory idiopathic inflammatory myopathies","volume":"60","author":"Dorph","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0285","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0290","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0295","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.rhu.0000182155.08982.60","article-title":"Rituximab in the treatment of refractory dermatomyositis","volume":"11","author":"Chiappetta","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0300","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0305","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2013.09.008_bib0310","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0315","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2013.09.008_bib0320","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jbspin.2007.10.010","article-title":"Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab","volume":"75","author":"Tournadre","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2013.09.008_bib0325","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficay and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0330","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0335","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/rheumatology\/kep147","article-title":"Efficacy of rituximab in refractory and relapsing myositis with anti-JO1\u00a0antibodies: a report of two cases","volume":"48","author":"Frikha","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0340","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.revmed.2013.09.008_bib0345","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0350","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0355","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.revmed.2011.11.017","article-title":"Antisynthetase syndrome: a retrospective study of 14\u00a0patients","volume":"33","author":"Dieval","year":"2012","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2013.09.008_bib0360","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.23571","article-title":"Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology","volume":"59","author":"Fathi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0365","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-JO1\u00a0patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2013.09.008_bib0370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rhum.2007.09.005","article-title":"Le rhumatologue face \u00e0 une myopathie cortisonique","volume":"75","author":"Tournadre","year":"2008","journal-title":"Rev Rhum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0375","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.autrev.2008.11.008","article-title":"The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies","volume":"8","author":"de Salles Painelli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2013.09.008_bib0380","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.22780","article-title":"Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis","volume":"57","author":"Alexanderson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2013.09.008_bib0385","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.22687","article-title":"Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial","volume":"57","author":"Chung","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631300670X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631300670X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:33:59Z","timestamp":1759336439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631300670X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S024886631300670X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2013.09.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge th\u00e9rapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies n\u00e9crosantes auto-immunes","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2013.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}